Novartis Ag (NVSEF) Change in Intangibles (2009 - 2026)
Novartis Ag's (NVSEF) quarterly Change in Intangibles came in at -$461.0 million in Q1 2026, down 12.99% quarter-over-quarter from -$408.0 million in Q4 2025.
Novartis Ag (NVSEF) Change in Intangibles (2009 - 2026) Analysis & Trends
Novartis Ag has disclosed Change in Intangibles across 12 years of filings, most recently posting -$461.0 million for Q1 2026.
- Change in Intangibles for Q1 2026 came in at -$461.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.6 billion (changed N/A YoY), and the FY2025 annual result was $164.0 million, up 105.0% from the prior year.
- Change in Intangibles came in at -$461.0 million for Q1 2026 at Novartis Ag, down from -$408.0 million in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of -$192.0 million in Q4 2022 to a low of -$929.0 million in Q1 2024.
- The 5-year median for Change in Intangibles is -$441.5 million (2023), against an average of -$442.8 million.
- Across the five-year window, Change in Intangibles soared 63.29% in 2023 and tumbled 320.36% in 2024, its largest moves.
- Novartis Ag's Change in Intangibles stood at -$192.0 million in 2022, then slumped by 96.35% to -$377.0 million in 2023, then sank by 51.99% to -$573.0 million in 2024, then advanced by 28.8% to -$408.0 million in 2025, then decreased by 12.99% to -$461.0 million in 2026.
- The last three Change in Intangibles figures came in at -$461.0 million (Q1 2026), -$408.0 million (Q4 2025), and -$477.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Intangibless (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -299.30 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | - | - | - | -461.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -461.00 Mn |
| Mar 31, 2026 | -461.00 Mn |
| Dec 31, 2025 | -408.00 Mn |
| Dec 31, 2025 | -408.00 Mn |
| Sep 30, 2025 | -477.00 Mn |
| Sep 30, 2025 | -477.00 Mn |
| Jun 30, 2025 | -227.00 Mn |
| Jun 30, 2025 | -227.00 Mn |
| Dec 31, 2024 | -573.00 Mn |
| Dec 31, 2024 | -573.00 Mn |
| Sep 30, 2024 | -478.00 Mn |
| Sep 30, 2024 | -478.00 Mn |
| Jun 30, 2024 | -468.00 Mn |
| Jun 30, 2024 | -468.00 Mn |
| Mar 31, 2024 | -929.00 Mn |
| Mar 31, 2024 | -929.00 Mn |
| Dec 31, 2023 | -377.00 Mn |
| Dec 31, 2023 | -377.00 Mn |
| Sep 30, 2023 | -422.00 Mn |
| Sep 30, 2023 | -422.00 Mn |